The Global Radiation-Induced Fibrosis Treatment Market Size was Worth USD 601 million in 2022 and is Estimated to Grow to USD 995 million by 2030, with a CAGR of Approximately 6.5 % Over the Forecast Period From 2023 To 2030.
Radiation-Induced Fibrosis Treatment Market Overview:
Radiation-induced fibrosis is a late-stage side effect of cancer treatment with external beam radiation therapy. Depending on the treatment site, it may manifest in the lungs, muscles, gastrointestinal and genitourinary systems, skin and subcutaneous tissue, or other organs. Numerous symptoms are produced as a result, and the quality of life is significantly impacted. Nerve stabilizers like Pregabalin/Gabapentin or Duloxetine are used to treat radiation-induced fibrosis during physical therapy. New therapeutic strategies, such as pentoxifylline and vitamin E combination, can treat radio-induced fibrosis that has already developed. The increased cancer incidence and pharmaceutical research and development improvements will accelerate the market expansion. The number of patients receiving radiotherapy or chemotherapy is likely to rise, and the use of cutting-edge drug delivery systems such as transdermal patches and combination therapies is expected to expand. Additionally, technological developments that lead to discovering new, high-potential pharmaceuticals impact the market, opening profitable opportunities.
One of the main causes of death on the globe is cancer. According to the National Institutes of Health (NIH), in 2018 approximately 1,735,350 new instances of cancer were found in the United States, and 609,640 people died from the condition. Rising cancer rates and pharmaceutical research and development advancements would support the market’s growth. In addition, the development of treatments for radiation-induced fibrosis is anticipated to be fueled by strong research and development in oncology, an increase in cancer cases, a growing preference for chemotherapy in cancer treatment, and the use of chemotherapy in conjunction with other cancer treatments.
The high cost of radiation-induced fibrosis treatment is expected to limit market expansion. Additionally, expensive research could limit the market’s expansion during the study time. Another concern likely to impede the market’s expansion in developing economies is the lack of data availability. Effective treatment has become more challenging due to a shortage of fresh treatment techniques for radiation-induced fibrosis.
The global radiation-induced fibrosis treatment market is segregated based on treatment type, route of administration, and end user.
- Based on treatment type, the market is divided into pharmaceuticals (corticosteroids, vitamin E, pirfenidone, NSAIDS), hyperbaric oxygen, physiotherapy, and microcurrent stimulation. Among these, the hyperbaric oxygen category led the market in 2021 and is expected to maintain its dominance throughout the forecast period. Inhaling pure oxygen at a pressure greater than one atmosphere absolute is known as hyperbaric oxygen therapy (HBO). It has been shown to enhance pulmonary function in people with radio-induced fibrosis.
- Based on the route of administration, the market is divided into oral and parenteral. The oral category dominated the market in 2021. Oral administration of medication is frequently used since it is the most patient-friendly and practical way. Compared to drugs provided in other methods, pharmaceuticals taken orally have a slower start and a longer but less strong effect. Due to its many advantages, oral medicine is the most used method of drug administration.
Radiation-Induced Fibrosis Treatment Market: Regional Landscape
- In 2021, North America dominated the market for radiation-induced fibrosis treatment because there are more cancer-relief organizations and campaigns in the US and Canada, which has increased cancer incidence. Additionally, it is anticipated that the market in the US will grow as cancer cases rise. Since 1.6 million people in the US were impacted by cancer in 2017, according to the American Cancer Society’s annual report, it is anticipated that cancer will hold the largest market share. The industry is expected to develop due to a variety of other factors, including beneficial government efforts and an increase in research partnership numbers.
- Due to the COVID-19 pandemic, the market for treatments for radiation-induced fibrosis has also suffered. Hospitals postponed the procurement of capital equipment and switched focus to COVID-19 treatment. The epidemic has also caused delays in installing equipment that has already been approved.
Radiation-Induced Fibrosis Treatment Market: Competitive Landscape
- Some of the main competitors dominating the global radiation-induced fibrosis treatment market include- Merck & Co. Inc., Galapagos NV, Biogen, Bristol-Myers Squibb Company, Prometic Life Sciences Inc., Cipla Inc., Pfizer, MediciNova, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Accord Healthcare, Zydus Cadila, and others.
Global Radiation-Induced Fibrosis Treatment Market is segmented as follows:
Radiation-Induced Fibrosis Treatment Market by Treatment Type Outlook (Revenue, USD Million, 2017 – 2030)
- Vitamin E
- Hyperbaric Oxygen
- Micro-current stimulation
Radiation-Induced Fibrosis Treatment Market by Route of Administration Outlook (Revenue, USD Million, 2017 – 2030)
Radiation-Induced Fibrosis Treatment Market by End User Outlook (Revenue, USD Million, 2017 – 2030)
- Ambulatory Surgical Centers
Radiation-Induced Fibrosis Treatment Market by Region Outlook (Revenue, USD Million, 2017 – 2030)
- North America
- The UK
- Rest of Europe
- Asia Pacific
- New Zealand
- South Korea
- Southeast Asia
- Rest of Southeast Asia
- The Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Rest of Latin America
|Radiation-Induced Fibrosis Treatment Market Report Scope
|Market Size Value in 2022
||USD 601 million
|Revenue Forecast in 2030
||USD 995 million
||CAGR of 6.5 % from 2023 to 2030
|Base Year for Estimation
||2017 – 2022
||2023 – 2030
||Revenue in USD million and CAGR from 2023 to 2030
||Revenue forecast, company ranking, Trends
competitive landscape, and growth factors
||Treatment Type, Route of Administration, End User, and Region
||North America; Europe; Asia Pacific; Latin America; Middle East & Africa
||U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico and Others
|Key Companies Profiled
||Merck & Co. Inc., Galapagos NV, Biogen, Bristol-Myers Squibb Company, Prometic Life Sciences Inc., Cipla Inc., Pfizer, MediciNova, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Accord Healthcare, Zydus Cadila, and others.